Role of nitroreductases but not cytochromes P450 in the metabolic activation of 1-nitropyrene in the HepG2 human hepatoblastoma cell line

Biochemical Pharmacology

Volumn 54, Issue 8, 1997, Pages 927-936

  Silvers, Kimberly J ^a   Couch, Letha H ^b   Rorke, Ellen A ^a   Howard, Paul C ^a,b  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Natl Ctr Toxicological Res F   (United States)

Author keywords

1 Nitropyrene; Cytochromes P450; DNA adducts; HepG2; Metabolic activation; Metabolism; Nitroreductase

Indexed keywords

1 NITROPYRENE; 2,3,7,8 TETRACHLORODIBENZO PARA DIOXIN; CYTOCHROME P450; NITROREDUCTASE;

ARTICLE; CELL LINE; CONTROLLED STUDY; DNA ADDUCT; HEPATOBLASTOMA; HEPATOMA CELL; HUMAN; HUMAN CELL; METABOLIC ACTIVATION; METABOLITE; MUTAGENICITY; OXIDATION; PRIORITY JOURNAL; REDUCTION; XENOBIOTIC METABOLISM;

BIOTRANSFORMATION; CARCINOMA, HEPATOCELLULAR; CYTOCHROME P-450 ENZYME SYSTEM; DNA ADDUCTS; HUMANS; LIVER; MUTAGENS; NITROREDUCTASES; PYRENES; TETRACHLORODIBENZODIOXIN; TUMOR CELLS, CULTURED;

EID: 0030876347     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(97)00268-2     Document Type: Article

References (83)

1. International Agency for Research on Cancer, Diesel and gasoline engine exhausts and some nitroarenes. IARC Monogr Eval Carcinog Risks Hum 46: 1-418, 1989.
2. Lewtas J and Nishioka M, Nitroarenes: Their detection, mutagenicity and occurrence in the environment. In: Nitroarenes: Occurrence, Metabolism and Biological Impact (Eds. Howard PC, Hecht SS and Beland FA), pp. 73-84. Plenum Press, New York, 1990.
3. Beland FA, Heflich RH, Howard PC and Fu PP, The in vitro metabolic activation of nitro polycyclic aromatic hydrocarbons. In: Polycyclic Hydrocarbons and Carcinogenesis (Ed. Harvey RG), pp. 371-396. American Chemical Society, Washington, DC, 1985.
4. Zielinska B, Arey J and Atkinson R, The atmospheric formation of nitroarenes and their occurrence in ambient air. In: Nitroarenes: Occurrence, Metabolism and Biological Impact (Eds. PC Howard, SS Hecht and FA Beland), pp. 85-93. Plenum Press, New York, 1990.
5. Tokiwa H and Ohnishi Y, Mutagenicity and carcinogenicity of nitroarenes and their sources in the environment. Crit Rev Toxicol 17: 23-60, 1986.
6. White CM, Nitrated Polycyclic Aromatic Hydrocarbons. Hurthig, Heidelberg, Germany, 1985.
7. Kanoh T, Fukuda M, Hayami E, Kinouchi T, Nishifuji K and Ohnishi Y, Nitro reaction in mice injected with pyrene during exposure to nitrogen dioxide. Mutat Res 245: 1-4, 1990.
8. Kinouchi T, Kataoka K, Miyanishi K, Howard PC, Kanoh T and Ohnishi Y, Effect of nitrogen-dioxide exposure on formation of nitrated metabolites in animals treated with polycyclic aromatic hydrocarbons. Environ Occupat Chem Hazards 2: 285-290, 1994.
9. Beland FA and Kadlubar FF, Metabolic activation and DNA adducts of aromatic amines and nitroaromatic hydrocarbons. In: Chemical Carcinogenesis and Mutagenesis I (Eds. Cooper CS and Grover PL), pp. 267-325. Springer, Berlin, 1990.
10. Rosenkranz HS and Mermelstein R, Mutagenicity and genotoxicity of nitroarenes. All nitro-containing chemicals were not created equal. Mutat Res 114: 217-267, 1983.
11. Howard PC, Heflich RH, Evans FE and Beland FA, Formation of DNA adducts in vitro and in Salmonella typhimurium upon metabolic reduction of the environmental mutagen 1-nitropyrene. Cancer Res 43: 2052-2056, 1983.
12. Heflich RH, Howard PC and Beland FA, 1-Nitrosopyrene: An intermediate in the metabolic activation of 1-nitropyrene to a mutagen in Salmonella typhimurium TA1538. Mutat Res 149: 25-32, 1985.
13. Heflich RH, Fullerton NF and Beland FA, An examination of the weak mutagenic response of 1-nitropyrene in Chinese hamster ovary cells. Mutat Res 161: 99-108, 1986.
14. Howard PC, Gerrard JA, Milo GE, Fu PP, Beland FA and Kadlubar FF, Transformation of normal human skin fibroblasts by 1-nitropyrene and 6-nitrobenzo[a]pyrene. Carcinogenesis 4: 353-355, 1983.
15. Howard PC, Reed KA and Koop DR, Oxidative metabolism of 1-nitropyrene by rabbit liver microsomes and purified microsomal cytochrome P450 isozymes. Cancer Res 48: 4261-4269, 1988.
16. Djurić Z, Fifer EK, Howard PC and Beland FA, Oxidative microsomal metabolism of 1-nitropyrene and DNA-binding of oxidized metabolites following nitroreduction. Carcinogenesis 7: 1073-1079, 1986.
17. Rosenkranz HS and Howard PC, Structural basis of the activity of nitrated polycyclic aromatic hydrocarbons. In: Carcinogenic and Mutagenic Effects of Diesel Engine Exhaust (Eds. Ishinishi I, Koizumi A, McClellan RO and Stöber W), pp. 141-168. Elsevier Science, Amsterdam, 1986.
18. Howard PC, DeMarco GJ, Consolo MC and McCoy GD, Differing effects of chronic ethanol consumption by mice on liver microsomal metabolism of xenobiotics: 1-nitropyrene, nicotine, aniline, and N-nitrosopyrrolidine. Mol Toxicol 1: 177-189, 1987.
19. El-Bayoumy K and Hecht SS, Identification and mutagenicity of metabolites of 1-nitropyrene formed by rat liver. Cancer Res 43: 3132-3137, 1983.
20. 14C]pyrene in the F344 rat. Cancer Res 44: 4317-4322, 1984.
21. El-Bayoumy K, Reddy B and Hecht SS, Identification of ring oxidized metabolites of 1-nitropyrene in the feces and urine of germfree F344 rats. Carcinogenesis 5: 1371-1373, 1984.
22. Consolo MC, Anders M and Howard PC, Mutagenicity of the phenolic microsomal metabolites of 3-nitrofluoranthene and 1-nitropyrene in strains of Salmonella typhimurium. Mutat Res 210: 263-269, 1989.
23. Howard PC, Aoyama T, Bauer SL, Gelboin HV and Gonzalez FJ, The metabolism of 1-nitropyrene by human cytochromes P450. Carcinogenesis 11: 1539-1542, 1990.
24. Silvers KJ, Chazinski T, McManus ME, Bauer SL, Gonzalez FJ, Gelboin HV, Maurel P and Howard PC, Cytochrome P-450 3A4 (nifedipine oxidase) is responsible for the C-oxidative metabolism of 1-nitropyrene in human liver microsomal samples. Cancer Res 52: 6237-6243, 1992.
25. Faust RA, Cheung MC and Albers JJ, Secretion of cholesteryl ester transfer protein-lipoprotein complexes by human HepG2 hepatocytes. Atherosclerosis 77: 77-82, 1989.
26. Wong SH, Fisher EA and Marsh JB, Effects of eicosapentaenoic and docosahexaenoic acids on apoprotein B mRNA and secretion of very low density lipoprotein in HepG2 cells. Arteriosclerosis 9: 836-841, 1989.
27. Pinkerton FD, Spilman CH, Via DP and Schroepfer GJ Jr, Differing effects of three oxysterols on low density lipoprotein metabolism in HepG2 cells. Biochem Biophys Res Commun 193: 1091-1097, 1993.
28. Everson GT and Polokoff MA, HepG2: A human hepatoblastoma cell line exhibiting defects in bile acid synthesis and conjugation. J Biol Chem 261: 2197-2201, 1986.
29. Diamond L, Cherian K, Harvey RG and DiGiovanni J, Mutagenic activity of methyl- and fluoro-substituted derivatives of polycyclic aromatic hydrocarbons in a human hepatoma (HepG2) cell-mediated assay. Mutat Res 136: 65-72, 1984.
30. Bhatt TS, Coombs M, DiGiovanni J and Diamond L, Mutagenesis in Chinese hamster cells by cyclopenta(a)phenanthrenes activated by a human hepatoma cell line. Cancer Res 43: 984-986, 1983.
31. DiGiovanni J, Singer JM and Diamond L, Comparison of the metabolic activation of 7,12-dimethylbenz(a)anthracene by a human hepatoma cell line (HepG2) and low passage hamster embryo cells. Cancer Res 44: 2878-2884, 1984.
32. Chang G, Jacobson-Kram D and Williams JR, Use of an established human hepatoma cell line with endogenous bio-activation for gene mutation studies. Cell Biol Toxicol 4: 267-279, 1988.
33. Dearfield KL, Jacobson-Kram D, Brown NA and Williams JR, Evaluation of a human hepatoma cell line as a target cell in genetic toxicology. Mutat Res 108: 437-449, 1983.
34. Silvers KJ, Eddy EP, McCoy EC, Rosenkranz HS and Howard PC, Pathways for the mutagenesis of 1-nitropyrene and dinitropyrenes in the human hepatoma cell line HepG2. Environ Health Perspect 102 (Suppl 6): 95-200, 1994.
35. Howard PC, Flammang TJ and Beland FA, Comparison of the in vitro and in vivo hepatic metabolites of the carcinogen 1-nitropyrene. Carcinogenesis 6: 243-249, 1985.
36. Howard PC, Beland FA and Cerniglia CE, Reduction of the carcinogen 1-nitropyrene to 1-aminopyrene by rat intestinal bacteria. Carcinogenesis 4: 985-990, 1983.
37. Eddy EP, Howard PC, McCoy GD and Rosenkranz HS, Mutagenicity, unscheduled DNA synthesis and metabolism of 1-nitropyrene in the human hepatoma cell line HepG2. Cancer Res 47: 3163-3168, 1987.
38. Lowry OH, Rosebrough NJ, Farr AL and Randall RJ, Protein measurement with the Folin phenol reagent. J Biol Chem 193: 265-275, 1951.
39. 32P-Postlabeling analysis of non-radioactive aromatic carcinogen-DNA adducts. Carcinogenesis 3: 1081-1092, 1982.
40. 32P-Postlabeling assay in mice of transplacental DNA damage induced by the environmental carcinogens safrole, 4-aminobiphenyl, and benzo(a)pyrene. Cancer Res 46: 3046-3054, 1986.
41. Smith BA, Korfmacher WA and Beland FA, DNA adduct formation in target tissues of Sprague-Dawley rats, CD-1 mice and A/J mice following tumorigenic doses of 1-nitropyrene. Carcinogenesis 11: 1705-1710, 1990.
42. Howard PC, McManus ME and Koop DR, The role of cytochrome P450 form 3b (P450 2C3) in untreated rabbit liver microsomal metabolism of 1-nitropyrene and 3-nitrofluoranthene. Biochem Toxicol 9: 71-78, 1994.
43. Johnson EF, Schwab GE and Muller-Eberhard U, Multiple forms of cytochrome P-450: Catalytic differences exhibited by two homogeneous forms of rabbit cytochrome P-450. Mol Pharmacol 15: 708-718, 1979.
44. Murray M and Reidy GF, Selectivity in the inhibition of mammalian cytochromes P-450 by chemical agents. Pharmacol Rev 42: 85-101, 1990.
45. Prichard L, Fahre I, Fabre G, Domergue J, Saint Aubert B, Mourad G and Maurel P, Cyclosporin A drug interactions. Screening for inducers and inhibitors of cytochrome P-450 (cyclosporin A oxidase) in primary cultures of human hepatocytes and in liver microsomes. Drug Metab Dispos 18: 595-606, 1990.
46. Daujat M, Pichard L, Dalet C, Larroque C, Bonfils C, Pompon D, Li D, Guzelian PS and Maurel P, Expression of five forms of microsomal cytochrome P-450 in primary cultures of rabbit hepatocytes treated with various classes of inducers. Biochem Pharmacol 36: 3597-3606, 1987.
47. Delaforge M, Jaouen M and Mansuy D, The cytochrome P-450 metabolite complex derived from troleandomycin: Properties in vitro and stability in vivo. Chem Biol Interact 51: 371-376, 1984.
48. Saito K, Kamataki T and Kato R, Participation of cytochrome P450 in reductive metabolism of 1-nitropyrenes by rat liver microsomes. Cancer Res 44: 3169-3173, 1984.
49. Mitchell CE, Effect of aryl hydrocarbon hydroxylase induction on the in vivo covalent binding of 1-nitropyrene, benzo[a]pyrene, 2-aminoanthracene, and phenanthridone to mouse lung deoxyribonucleic acid. Biochem Pharmacol 34: 545-551, 1985.
50. Beliasario MA, Carrano L, de Giulio A and Buonocore V, Role of rat liver inducible enzymes in in vitro metabolic transformation of 1-nitropyrene. Toxicol Lett 32: 89-96, 1986.
51. Sassa S, Sugita O, Galbraith RA and Kapp A, Drug metabolism by the human hepatoma cell line, HepG2. Biochem Biophys Res Commun 142: 52-57, 1987.
52. Fukuda Y and Sassa S, Suppression of cytochrome P450IA1 by interleukin-6 in human HepG2 hepatoma cells. Biochem Pharmacol 47: 1187-1195, 1994.
53. Fukuda Y, Ishida N, Noguchi T, Kappas A and Sassa S, Interleukin-6 down regulates the expression of transcripts encoding cytochrome P450 IA1, IA2, and IIIA3 in human hepatoma cells. Biochem Biophys Res Commun 184: 960-965, 1992.
54. Sirica AE and Pitot HC, Drug metabolism and effects of carcinogens in cultured hepatic cells. Pharmacol Rev 31: 205-228, 1979.
55. Doodstar H, Duthie SJ, Burke MD, Melvin WT and Grant MH, The influence of culture medium composition on drug metabolizing enzyme activities of the human liver derived HepG2 cell line. FEBS Lett 241: 15-18, 1988.
56. Guillouzo A, Morel F, Fardel O and Meunier B, Use of human hepatocyte cultures for drug metabolism studies. Toxicology 82: 209-219, 1993.
57. Schuetz EG, Schuetz JD, Strom SC, Thompson MT, Fisher RA, Molowa DT, Li D and Guzelian PS, Regulation of human liver cytochromes P-450 in family 3A in primary and continuous culture of human hepatocytes. Hepatology 18: 1254-1262, 1993.
58. Molowa DT, Schuetz EG, Wrighton SA, Watkins PB, Kremers P, Mendez-Picon G and Parker A, Complete cDNA sequence of a cytochrome P-450 inducible by glucocorticoids in human liver. Proc Natl Acad Sci USA 83: 5311-5315, 1986.
59. Kitada M, Kamataki T, Itahashi K, Rikihisa T and Kanakubo Y, P-450 HFLa, a form of cytochrome P-450 purified from human fetal livers, is the 16-α-hydroxylase of dehydroepiandrosterone 3-sulfate. J Biol Chem 262: 13534-13537, 1987.
60. Wrighton SA, Molowa DT and Guzelian PS, Identification of a cytochrome P-450 in human fetal liver related to glucocorticoid-inducible cytochrome P-450HLp in the adult. Biochem Pharmacol 37: 3053-3055, 1988.
61. Wrighton SA and Vandenbranden M, Isolation and characterization of human fetal liver cytochrome P-450HLp2: A third member of the P450III gene family. Arch Biochem Biophys 268: 144-151, 1989.
62. Doodstar H, Grant MH, Melvin WT, Wolf CR and Burke MD, The effects of inducing agents on cytochrome P450 and UDP-glucuronyltransferase activities in human HepG2 hepatoma cells. Biochem Pharmacol 46: 629-635, 1993.
63. Dawson JR, Adams DJ and Wolf CR, Induction of drug metabolizing enzymes in human liver cell line HepG2. FEBS Lett 183: 219-222, 1985.
64. Belisario MA, Arena AR, Pecce R, Borgia R, Staiano N and DeLorenzo F, Effect of enzyme inducers on metabolism of 1-nitropyrene in human hepatoma cell line HepG2. Chem Biol Interact 78: 253-268, 1991.
65. 1-450 gene expression by 2,3,7,8-tetrachlorodibenzo-p-dioxin in human tissue culture cell lines. Arch Biochem Biophys 253: 233-240, 1987.
66. Labruzzo P, Yu XF and Dufresne MJ, Induction of aryl hydrocarbon hydroxylase and demonstration of a specific nuclear receptor for 2,3,7,8-tetrachlorodibenzo-p-dioxin in two human hepatoma cell lines. Biochem Pharmacol 38: 2339-2348, 1989.
67. Merchant M, Morrison V, Santostefano M and Safe S, Mechanism of action of aryl hydrocarbon receptor antagonists: Inhibition of 2,3,7,8-tetrachlorodibenzo-p-dioxin-induced CYP1A1 gene expression. Arch Biochem Biophys 298: 389-394, 1992.
68. McManus ME, Burgess WM, Veronese ME, Huggett A, Quattrochi LC and Tukey RH, Metabolism of 2-acetylamino-fluorene and benzo[a]pyrene and activation of food-derived heterocyclic amine mutagens by human cytochromes P-450. Cancer Res 50: 3367-3376, 1990.
69. Quattrochi LC and Tukey RH, The human cytochrome CYP1A2 gene contains regulatory elements responsive to 3-methylcholanthrene. Mol Pharmacol 36: 66-71, 1989.
70. Shimada T, Hayes CL, Yamazaki H, Amin S, Hecht SS, Guengerich FP and Sutler TR, Activation of chemically diverse procarcinogens by human cytochrome P-450 1B1. Cancer Res 56: 2979-2984, 1996.
71. Ohgaki H, Matsudura N, Morino K, Kawachi T, Sugimura T, Morita K, Tokiwa H and Hirota T, Carcinogenicity in rats of the mutagenic compounds 1-nitropyrene and 3-nitrofluoranthene. Cancer Lett 15: 1-17, 1982.
72. Ohgaki H, Hasejawa H, Kato T, Negishi C, Sato S and Sugimura T, Absence of carcinogenicity of 1-nitropyrene, correction of previous results, and new demonstration of carcinogenicity of 1,6-dinitropyrene in rats. Cancer Lett 25: 239-245, 1985.
73. El-Bayoumy K, Hecht SS and Hoffman D, Comparative tumor initiating activity on mouse skin of 6-nitrobenzo[a]pyrene, 6-nitrochrysene, 3-nitroperylene, 1-nitropyrene, and their parent hydrocarbons. Cancer Lett 16: 333-337, 1982.
74. Nesnow S, Triplett JL and Slaga TJ, Tumor initiating activity of 1-nitropyrene and its nitrated products in SENCAR mice. Cancer Lett 23: 1-8, 1984.
75. Tokiwa H, Otofuji T, Horikawa K, Kitamori S, Otsuka H, Manabe Y, Kinouchi T and Ohnishi Y, 1,6-Dinitropyrene: Mutagenicity in Salmonella and carcinogenicity in BALB/c mice. JNCI 73: 1359-1363, 1984.
76. Maeda T, Izumi K, Otsuka II, Manabe Y, Kinouchi T and Ohnishi Y, Induction of squamous cell carcinoma in the rat lung by 1,6-dinitropyrene. JNCI 76: 693-697, 1986.
77. Hirose M, Lee M-S, Wang CY and King CM, Induction of rat mammary gland tumors by 1-nitropyrene, a recently recognized environmental mutagen. Cancer Res 44: 1158-1162, 1984.
78. El-Bayoumy K, Rivenson A, Johnson B, DiBello J, Little P and Hecht SS, Comparative tumorigenicity of 1-nitropyrene, 1-nitrosopyrene, and 1-aminopyrene administered by gavage to Sprague-Dawley rats. Cancer Res 48: 4256-4260, 1988.
79. Imaida K, Hirose M, Tay L, Lee MS, Wang CY and King CM, Comparative carcinogenicities of 1-, 2-and 4-nitropyrene and structurally related compounds in the female CD rat. Cancer Res 51: 2902-2907, 1991.
80. Wislocki PG, Bagan ES, Lu AYH, Dooley KL, Fu PP, Han-Hsu H, Beland FA and Kadlubar FF, Tumorigenicity of nitrated derivatives of pyrene, benzo[a]anthracene, chrysene, and benzo[a]pyrene in the newborn mouse assay. Carcinogenesis 7: 1317-1322, 1986.
81. Maeda K, Tetsuya K, Nagai T and Kato R, Postnatal development of constitutive forms of cytochrome P-450 in liver microsomes of male and female rats. Biochem Pharmacol 33: 509-512, 1984.
82. Cresteil T, Beaune P, Celier C, Leroux JP and Guengerich FP, Cytochrome P-450 isoenzyme content and monooxygenase activities in rat liver: Effect of ontogenesis and pretreatment by phenobarbital and 3-methylcholanthrene. J Pharmacol Exp Ther 236: 269-276, 1986.
83. Bonfils C, Combalbert J, Pineau T, Angevin J, Larroque C, Derancourt J, Capony JP and Maurel P, Ontogenesis of rabbit liver cytochrome P450: Evidence for a cytochrome P450-IIe (3a)-related form prevailing during the post-natal period. Eur J Biochem 188: 187-194, 1990.